Related Experiment Videos
[News on therapies for uveitis]
1Centre Médical Académique, Université d'Amsterdam, Pays-Bas.
Journal Francais D'Ophtalmologie
|June 25, 2005
Summary
Managing uveitis involves balancing immunosuppression with side effect prevention. Strategies include drug selection, preventive measures, and local delivery for effective treatment with reduced risks.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Uveitis treatment necessitates immunosuppression, achievable via conventional agents or targeted anti-inflammatory modulators.
- Minimizing treatment-related side effects is crucial for patient safety and therapeutic success.
Purpose of the Study:
- To review strategies for managing immunosuppression in uveitis, focusing on side effect limitation.
- To discuss the roles of intraocular triamcinolone and Remicade (anti-TNF-alpha) in uveitis therapy.
Main Methods:
- Review of current therapeutic approaches for uveitis, including drug selection and administration routes.
- Discussion of specific drug profiles, potential complications, and preventive measures.
Main Results:
- Intraocular triamcinolone offers high local dosage without systemic effects but carries a risk of pressure elevation and requires specific precautions.
- Remicade, a TNF-alpha inhibitor, shows promise for severe, refractory uveitis and is under clinical investigation.
Conclusions:
- Careful patient selection and administration strategies are vital for optimizing immunosuppressive therapy in uveitis.
- Both local corticosteroid delivery and novel biologics like Remicade represent important advancements in uveitis management.